ACADIA Pharmaceuticals Inc. [NASDAQ: ACAD] traded at a high on 09/18/20, posting a 4.07 gain after which it closed the day’ session at $42.42. The company report on September 5, 2020 that (ACAD) Alert: Johnson Fistel Announces Shareholder Class Action Against ACADIA Pharmaceuticals Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses?.
Johnson Fistel, LLP is investigating potential claims on behalf of ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD) (“ACADIA” or the “Company”) against certain of its officers and directors. Specifically, a class-action lawsuit pending in the United States District Court for the Southern District of California against ACADIA and certain of its current and former officers recently survived, in part, certain defendants’ attempts to have the case dismissed.
According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (1) adverse events and safety concerns related to NUPLAZID threatened the drug’s initial and continuing FDA approval; (2) ACADIA engaged in business practices likely to attract regulatory scrutiny; and (3) as a result, defendants’ statements about ACADIA’s business, operations, and prospects, were materially false and misleading and lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
The results of the trading session contributed to over 2423693 shares changing hands. Over the past one week, the price volatility of ACADIA Pharmaceuticals Inc. stands at 4.06% while the volatility over the past one month is 3.44%.
The market cap for ACAD stock reached $6.47 billion, with 156.54 million shares outstanding and 115.75 million shares in the current float. Compared to the average trading volume of 1.89M shares, ACAD reached a trading volume of 2423693 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about ACADIA Pharmaceuticals Inc. [ACAD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACAD shares is $59.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACAD stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for ACADIA Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 25, 2020. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Overweight. The new note on the price target was released on August 20, 2020, representing the official price target for ACADIA Pharmaceuticals Inc. stock. Previously, the target price had yet another raise from $41 to $71, while Stifel kept a Buy rating on ACAD stock.
The Average True Range (ATR) for ACADIA Pharmaceuticals Inc. is set at 1.43, with the Price to Sales ratio for ACAD stock in the period of the last 12 months amounting to 16.47. The Price to Book ratio for the last quarter was 10.00, with the Price to Cash per share for the same quarter was set at 4.31.
How has ACAD stock performed recently?
ACADIA Pharmaceuticals Inc. [ACAD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.84. With this latest performance, ACAD shares gained by 9.03% in over the last four-week period, additionally plugging by 27.12% over the last 6 months – not to mention a rise of 1.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACAD stock in for the last two-week period is set at 64.35, with the RSI for the last a single of trading hit 72.32, and the three-weeks RSI is set at 54.94 for ACADIA Pharmaceuticals Inc. [ACAD]. The present Moving Average for the last 50 days of trading for this stock 42.30, while it was recorded at 39.96 for the last single week of trading, and 44.41 for the last 200 days.
ACADIA Pharmaceuticals Inc. [ACAD]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ACADIA Pharmaceuticals Inc. [ACAD] shares currently have an operating margin of -72.71 and a Gross Margin at +96.65. ACADIA Pharmaceuticals Inc.’s Net Margin is presently recorded at -69.38.
Return on Total Capital for ACAD is now -41.51, given the latest momentum, and Return on Invested Capital for the company is -39.72. Return on Equity for this stock declined to -39.93, with Return on Assets sitting at -35.55. When it comes to the capital structure of this company, ACADIA Pharmaceuticals Inc. [ACAD] has a Total Debt to Total Equity ratio set at 1.40. Additionally, ACAD Total Debt to Total Capital is recorded at 1.38, with Total Debt to Total Assets ending up at 1.25. Long-Term Debt to Equity for the company is recorded at 0.91, with the Long-Term Debt to Total Capital now at 0.90.
Reflecting on the efficiency of the workforce at the company, ACADIA Pharmaceuticals Inc. [ACAD] managed to generate an average of -$467,712 per employee. Receivables Turnover for the company is 10.33 with a Total Asset Turnover recorded at a value of 0.51.ACADIA Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.50.
Earnings analysis for ACADIA Pharmaceuticals Inc. [ACAD]
With the latest financial reports released by the company, ACADIA Pharmaceuticals Inc. posted -0.29/share EPS, while the average EPS was predicted by analysts to be reported at -0.4/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 27.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACAD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ACADIA Pharmaceuticals Inc. go to 25.00%.
Insider trade positions for ACADIA Pharmaceuticals Inc. [ACAD]
There are presently around $6,483 million, or 98.00% of ACAD stock, in the hands of institutional investors. The top three institutional holders of ACAD stocks are: BAKER BROS. ADVISORS LP with ownership of 41,904,586, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; FMR LLC, holding 20,790,304 shares of the stock with an approximate value of $881.92 million in ACAD stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $481.12 million in ACAD stock with ownership of nearly -4.11% of the company’s market capitalization.
Positions in ACADIA Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 162 institutional holders increased their position in ACADIA Pharmaceuticals Inc. [NASDAQ:ACAD] by around 13,397,945 shares. Additionally, 124 investors decreased positions by around 15,659,414 shares, while 43 investors held positions by with 123,770,288 shares. The mentioned changes placed institutional holdings at 152,827,647 shares, according to the latest SEC report filing. ACAD stock had 79 new institutional investments in for a total of 3,273,025 shares, while 27 institutional investors sold positions of 1,737,728 shares during the same period.